Trastuzumab Deruxtecan Type II Variation Application Validated by EMA for the Treatment of HER2 Positive Advanced Gastric CancerBusiness Wire • 11/03/21
AstraZeneca's premium growth story still not appreciated by the market, leading investment bank saysProactive Investors • 11/02/21
AstraZeneca Awards 30 Nonprofit Organizations through the ACT on Health Equity Community Solutions Challenge to Actively Address Health DisparitiesBusiness Wire • 11/01/21
AstraZeneca's Imfinzi/Chemo Combo Strikes First Immunotherapy Wins In Bile Duct Cancer TrialBenzinga • 10/26/21
Second Clinical Trial Collaboration Initiated to Evaluate Datopotamab Deruxtecan in Combination with KEYTRUDA® (pembrolizumab) in Patients with Metastatic Non-Small Cell Lung CancerBusiness Wire • 10/25/21
AstraZeneca posts stellar late-stage trial results for advanced biliary tract cancer candidateProactive Investors • 10/25/21
Can AstraZeneca's COVID Antibody Therapy Win Against Regeneron and Eli Lilly?The Motley Fool • 10/23/21
AstraZeneca and Bob Harper Unveil the Survivors Have Heart Second Chance Portraits to Change the Face of Heart Attack SurvivorshipBusiness Wire • 10/21/21
AstraZeneca 'top pick' in pharma sector as JP Morgan predicts big growth aheadProactive Investors • 10/21/21
AstraZeneca Announces Winners and Recognizes Oncology Change Makers in Third Annual Cancer Community AwardsBusiness Wire • 10/20/21
Pfizer and AstraZeneca vaccines were effective as prior infection, U.K. study findsMarket Watch • 10/18/21
AstraZeneca says phase III trial shows Imfinzi and tremelimumab combination improves liver cancer survival rateProactive Investors • 10/15/21